Pet Drug Reports

Drugs by active ingredient › Amoxicillin + Clavulanate Potassium

Drug · combination of 2 active ingredients

Amoxicillin + Clavulanate Potassium: adverse event reports

All products with this ingredient combination · 1 FDA-approved application in the Green Book

2,319reports naming this combination, 2002–20260.2% of all reports · about 97 a year
211reports, 12 months to March 2026187 in the 12 months before
46%classed serious, as reportedof 1,700 reports stating it
13.5%record death or euthanasia, as reported313 reports
52.7%of reports concern dogs0.1% of all dog reports

Between May 2002 and March 2026 FDA received 2,319 adverse event reports listing a drug with the combination amoxicillin and clavulanate potassium as the recorded active ingredients. The Green Book lists 1 FDA-approved application with exactly this combination.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient combination across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 211 reports named it, up 13% from 187 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 97 reports a year and 0.2% of all 1,357,245 reports (0.1% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are color, Abnormal (20.1%), vomiting (16.6%) and lethargy (15.4%). A report can list several signs, so shares add to more than 100%; 1,367 different terms appear across these reports. Color, Abnormal appears in 20.1% of these reports, a smaller share than in the pooled reports for every drug containing clavulanate potassium (37.5%).

52.7% of reports concern dogs. Not every report describes illness: 10.4% were filed wholly or partly as lack of expected effectiveness and 26.7% as product or packaging defects. Of reports that state seriousness, 46% were classed as serious, and 13.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog403 · peak 20
Apr 2021: 5Jun 2021: 2Jul 2021: 4Aug 2021: 2Sep 2021: 2Oct 2021: 2Nov 2021: 8Dec 2021: 1Jan 2022: 6Feb 2022: 4Mar 2022: 2Apr 2022: 3May 2022: 4Jun 2022: 1Jul 2022: 3Aug 2022: 3Sep 2022: 1Oct 2022: 3Nov 2022: 1Dec 2022: 2Feb 2023: 3Mar 2023: 4Apr 2023: 7May 2023: 5Jun 2023: 6Jul 2023: 8Aug 2023: 4Sep 2023: 8Oct 2023: 8Nov 2023: 5Dec 2023: 9Jan 2024: 7Feb 2024: 12Mar 2024: 8Apr 2024: 5May 2024: 11Jun 2024: 9Jul 2024: 7Aug 2024: 11Sep 2024: 11Oct 2024: 9Nov 2024: 8Dec 2024: 10Jan 2025: 9Feb 2025: 10Mar 2025: 11Apr 2025: 5May 2025: 20Jun 2025: 12Jul 2025: 15Aug 2025: 10Sep 2025: 14Oct 2025: 9Nov 2025: 12Dec 2025: 7Jan 2026: 10Feb 2026: 12Mar 2026: 132022202320242025
Cat198 · peak 9
Aug 2021: 1Oct 2021: 2Nov 2021: 1Jan 2022: 1Mar 2022: 1Apr 2022: 1May 2022: 2Jun 2022: 2Aug 2022: 2Sep 2022: 2Oct 2022: 5Nov 2022: 1Dec 2022: 3Jan 2023: 2Feb 2023: 3Mar 2023: 3Apr 2023: 5May 2023: 2Jun 2023: 4Jul 2023: 1Aug 2023: 3Sep 2023: 9Oct 2023: 4Nov 2023: 1Dec 2023: 5Jan 2024: 3Feb 2024: 2Mar 2024: 9Apr 2024: 4May 2024: 6Jun 2024: 5Jul 2024: 1Aug 2024: 2Sep 2024: 5Oct 2024: 5Nov 2024: 9Dec 2024: 3Jan 2025: 6Feb 2025: 8Mar 2025: 7Apr 2025: 3May 2025: 3Jun 2025: 6Jul 2025: 4Aug 2025: 6Sep 2025: 9Oct 2025: 5Nov 2025: 5Dec 2025: 1Jan 2026: 9Feb 2026: 4Mar 2026: 22022202320242025
Horse0 · peak 1
2022202320242025
Other49 · peak 5
Jan 2022: 1Mar 2022: 1May 2022: 1Mar 2023: 1Apr 2023: 2May 2023: 2Jun 2023: 1Jul 2023: 2Sep 2023: 2Dec 2023: 3Jan 2024: 1Mar 2024: 2Apr 2024: 1Jun 2024: 1Jul 2024: 1Aug 2024: 3Oct 2024: 2Jan 2025: 5Feb 2025: 2Apr 2025: 3May 2025: 3Jul 2025: 1Aug 2025: 3Sep 2025: 1Oct 2025: 2Jan 2026: 1Feb 2026: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

01933862002: 120022003: 62005: 720052006: 32008: 120082010: 12011: 120112012: 162013: 13820132014: 3862015: 36120152016: 3342017: 25320172018: 362019: 5020192020: 622021: 4320212022: 562023: 12220232024: 1732025: 21720252026: 52

2026 covers reports received through March 2026 only.

Signs listed in reports

share of amoxicillin + clavulanate potassium reports listing the termall drugs containing clavulanate potassiumall dog reports

  1. Color, Abnormal[a product quality report, not a sign in an animal]20.1%465
  2. Vomiting16.6%385
  3. Lethargy[unusually tired or inactive]15.4%357
  4. Anorexia[not eating]9.5%220
  5. No sign[no clinical sign was reported]9.3%216
  6. Other abnormal test result NOS[abnormal laboratory result, type not specified]9.1%210
  7. Diarrhoea[diarrhea]8.1%187
  8. Death by euthanasia[the animal was euthanized]7.6%177
  9. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]6.4%149
  10. Uncoded sign[a sign with no matching dictionary term]5.6%130
  11. Fever5.6%129
  12. Death5.5%127
  13. Leucocytosis NOS[high white blood cell count]5.4%125
  14. Suspension, Abnormal[a product quality report, not a sign in an animal]5.1%119
  15. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]5%117
  16. Anaemia NOS[low red blood cell count]5%116
  17. Lack of efficacy - NOS[the product did not have the expected effect]5%115
  18. Behavioural disorder NOS[behaviour change, type not specified]4.3%100
  19. Seizure NOS[seizure, type not specified]4.3%100
  20. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]4.1%95
  21. Ataxia[unsteady, uncoordinated movement]3.7%86
  22. Neutrophilia[high neutrophil count]3.7%86
  23. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]3.4%80
  24. Hyperglycaemia[high blood sugar]2.9%67

Top 30 of 1,367 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal13.4%310
Recovered with Sequela0.4%9
Ongoing30.9%716
Died5.9%137
Euthanized7.6%177
Outcome Unknown16.3%379

What kind of report it was

Safety issue62.8%1,457
Lack of expected effectiveness2.2%51
Both safety and lack of expected effectiveness8.2%190
Manufacturing or product defect26.7%619
Other0.1%2

Coloured bar: reports naming amoxicillin + clavulanate potassium. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog52.7%1,222
Cat21.3%493
Human exposure0.2%5
Other0%1
Other Birds0%1
Parrot0%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year10.4%242
1 to 3 years10%232
4 to 7 years16.3%378
8 to 11 years18.3%424
12 years and over17.2%398
Age not given27.8%645

Weight of the animal

Under 5 kg (11 lb)22%511
5 to 9.9 kg (11–22 lb)20.4%472
10 to 24.9 kg (22–55 lb)13.6%316
25 to 44.9 kg (55–99 lb)13%301
45 kg and over (99 lb+)1.3%31
Weight not given29.7%688

Route of administration stated in reports: oral (1,297), subcutaneous (3), auricular (otic) (2), ophthalmic (2), topical (2), other (1).

In context

MeasureAmoxicillin + Clavulanate PotassiumAll drugs containing clavulanate potassiumAll dog reportsAll reports
Reports2,3198,064985,6751,357,245
Share of that pool's reports naming this drug—28.8%0.1%0.2%
Classed serious, of reports stating it46%46.2%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports135895563.8
Filed as lack of expected effectiveness (wholly or partly)10.4%——23%
Top term, share of reportsColor, Abnormal 20.1%37.5%0%—

The clavulanate potassium pool is every report naming clavulanate potassium alone or in any combination; this combination accounts for 28.8% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Amoxicillin8,627184
Amoxicillin Trihydrate + Clavulanate Potassium5,462385
Amoxicillin + Amoxicillin Trihydrate + Clavulanate Potassium2561
Clavulanate Potassium303

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing this combination (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Only one approved application matches this ingredient set. FDA's records still do not say which product a report concerned: the same ingredients are also dispensed as compounded, foreign-labelled and unapproved products, and the ingredient field is completed by whoever submitted the report.

Trade nameActive ingredientsSponsorApproved forApplication
KesiumAmoxicillin, Clavulanate PotassiumCeva Sante AnimaleDogs, CatsANADA 200-749

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about amoxicillin + clavulanate potassium reports

How many adverse event reports has FDA received for the combination amoxicillin and clavulanate potassium?

2,319 reports record a drug with the combination amoxicillin and clavulanate potassium as its active ingredients in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 211 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 1 approved application with this combination; the reference list on this page names them without any counts.

What signs are reported most often?

color, Abnormal (20.1%), vomiting (16.6%), lethargy (15.4%), anorexia (9.5%) and no sign (9.3%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (52.7%), cat (21.3%) and human exposure (0.2%). Among single-breed animals the most frequent labels are Domestic Shorthair, Labrador Retriever, Chihuahua and Shih Tzu; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

211 reports in the 12 months to March 2026, up 13% from 187 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that amoxicillin + clavulanate potassium harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of amoxicillin + clavulanate potassium?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.